In an article that has become an unofficial mantra among cannabis advocates in Washington, D.C., the medicinal properties of eufraia plant medicine are touted as being able to fight chronic pain, anxiety, depression and other psychiatric illnesses.
The plant’s medicinal properties are similar to those of the medicine used to treat the rare and devastating form of cancer known as non-Hodgkin’s lymphoma.
But critics say the plant is not safe for humans, and that it can cause serious side effects, such as cancer and seizures, that are not present in cannabis.
That’s because the plant contains high levels of a compound called cannabidiol (CBD), which can be converted to THC, the psychoactive ingredient in marijuana.
The THC can cause those symptoms.
But even if you are protected by CBD, the plant may not help you fight an illness that’s not a cannabis problem, said John R. Bennett, an associate professor of pharmacology at the University of Maryland School of Pharmacy who studies the plant.
And he said the plant also has potential side effects.
For example, it’s possible to get high and go into an episode of psychosis when you take the medication, said Bennett, a professor of psychiatry and the director of the Johns Hopkins Center for Cannabis Research.
The side effects of the drug, he said, include anxiety, paranoia, confusion and delusions, as well as seizures, irritability and irritability.
Bennett also worries about the effect on people who have not taken medical cannabis for years.
“It’s an untested, untested drug,” he said.
“There’s a huge amount of research that shows that it’s not safe.”
Critics also say that the CBD content of eufloria plant medicine is too low to be beneficial for chronic pain.
That could be because it contains far too much THC, Bennett said.
The FDA has approved more than 100 drugs to treat a variety of conditions, including cancer, multiple sclerosis, Crohn’s disease, epilepsy and glaucoma.
But Bennett said the CBD in euploria plant is far too low, even for people who do not have any other side effects from medical cannabis.
The federal government has approved hundreds of compounds for use in medicine, but only one has been approved for use to treat people with epilepsy.
And a number of the CBD compounds in eufracia plant have not been tested for safety, according to the American Academy of Neurology.
Bennett said that if the FDA approves a new drug, it should be tested for CBD, as it has for THC.
The DEA has said it will consider testing the CBDs for safety once the agency approves the new drug.
But in the meantime, the FDA has already rejected more than two dozen medical marijuana compounds because of CBD levels below the 5 milligrams per milliliter limit set by the Food and Drug Administration.
“That’s a real concern,” Bennett said of the FDA’s approval.
“We need to have that review process, to ensure that CBD doesn’t go into the system and end up in a medicine that could be harmful.”
Bennett said he believes the FDA will soon decide whether to approve CBD-containing medications.
“They’re going to make that decision very soon,” he added.
In response to the DEA’s approval of CBD, Bennett and his colleague, John F. Kohn, a clinical pharmacologist at the Johns the Hopkins University School of Medicine, are writing to the agency asking that it take a look at whether there are any other CBD-based medicines to take and to evaluate whether they can be approved.
They also want the FDA to study whether the CBD-drug approval process is working and whether there is sufficient evidence that CBD is safe and effective for treating certain illnesses.
Bennett and Kohn say the DEA has given the FDA “very little” time to study the CBD plant medicine.
In a statement, the DEA said it was reviewing Bennett and company’s request.
“As we have said before, we have a strong interest in working with the industry and other experts to make a comprehensive assessment of the potential benefits of CBD-type compounds for the prevention and treatment of a wide range of diseases and conditions,” the agency said.
It said the agency will take public comments through May 3.
The Department of Health and Human Services has already said it’s reviewing the medical marijuana applications, but the agency has not released any final decisions on CBD-related drugs.
The agency has previously said it would take no position on the applications because it has no plans to approve them.
“I would be surprised if we didn’t hear more about CBD in the near future,” Bennett, of Johns Hopkins, said.
Some of the companies that have applied for CBD-medicinal status have already filed applications with the FDA.
In the meantime.
the DEA approved more CBD-derived drugs for use as